Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 1
2015 1
2016 3
2017 1
2018 1
2020 2
2021 2
2022 4
2023 2
2024 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Andtbacka RH, et al. J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26. J Clin Oncol. 2015. PMID: 26014293 Clinical Trial.
Overall response rate was also higher in the T-VEC arm (26.4%; 95% CI, 21.4% to 31.5% v 5.7%; 95% CI, 1.9% to 9.5%). Median OS was 23.3 months (95% CI, 19.5 to 29.6 months) with T-VEC and 18.9 months (95% CI, 16.0 to 23.7 months) with GM-CSF (hazard ratio, 0.79; 95% CI, 0. …
Overall response rate was also higher in the T-VEC arm (26.4%; 95% CI, 21.4% to 31.5% v 5.7%; 95% CI, 1.9% to 9.5%). Median OS was 23 …
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, Kawecki A, Girotto G, Alvarez Avitia MA, Even C, Toledo JGR, Guminski A, Müller-Richter U, Kiyota N, Roberts M, Khan TA, Miller-Moslin K, Wei L, Argiris A. Haddad RI, et al. J Clin Oncol. 2023 Apr 20;41(12):2166-2180. doi: 10.1200/JCO.22.00332. Epub 2022 Dec 6. J Clin Oncol. 2023. PMID: 36473143 Free PMC article. Clinical Trial.
There were no statistically significant differences in OS with nivolumab plus ipilimumab versus EXTREME in the all randomly assigned (median: 13.9 v 13.5 months; hazard ratio [HR], 0.95; 97.9% CI, 0.80 to 1.13; P = .4951) and CPS 20 (median: 17.6 v 14.6 months; HR …
There were no statistically significant differences in OS with nivolumab plus ipilimumab versus EXTREME in the all randomly assigned (median …
25th Annual Computational Neuroscience Meeting: CNS-2016.
Sharpee TO, Destexhe A, Kawato M, Sekulić V, Skinner FK, Wójcik DK, Chintaluri C, Cserpán D, Somogyvári Z, Kim JK, Kilpatrick ZP, Bennett MR, Josić K, Elices I, Arroyo D, Levi R, Rodriguez FB, Varona P, Hwang E, Kim B, Han HB, Kim T, McKenna JT, Brown RE, McCarley RW, Choi JH, Rankin J, Popp PO, Rinzel J, Tabas A, Rupp A, Balaguer-Ballester E, Maturana MI, Grayden DB, Cloherty SL, Kameneva T, Ibbotson MR, Meffin H, Koren V, Lochmann T, Dragoi V, Obermayer K, Psarrou M, Schilstra M, Davey N, Torben-Nielsen B, Steuber V, Ju H, Yu J, Hines ML, Chen L, Yu Y, Kim J, Leahy W, Shlizerman E, Birgiolas J, Gerkin RC, Crook SM, Viriyopase A, Memmesheimer RM, Gielen S, Dabaghian Y, DeVito J, Perotti L, Kim AJ, Fenk LM, Cheng C, Maimon G, Zhao C, Widmer Y, Sprecher S, Senn W, Halnes G, Mäki-Marttunen T, Keller D, Pettersen KH, Andreassen OA, Einevoll GT, Yamada Y, Steyn-Ross ML, Alistair Steyn-Ross D, Mejias JF, Murray JD, Kennedy H, Wang XJ, Kruscha A, Grewe J, Benda J, Lindner B, Badel L, Ohta K, Tsuchimoto Y, Kazama H, Kahng B, Tam ND, Pollonini L, Zouridakis G, Soh J, Kim D, Yoo M, Palmer SE, Culmone V, Bojak I, Ferrario A, Merrison-Hort R, Borisyuk R, Kim CS, Tezuka T, Joo P, Rho YA, Burt… See abstract for full author list ➔ Sharpee TO, et al. BMC Neurosci. 2016 Aug 18;17 Suppl 1(Suppl 1):54. doi: 10.1186/s12868-016-0283-6. BMC Neurosci. 2016. PMID: 27534393 Free PMC article.
Kim, Shang Mu, Kevin L. Briggman, H. Sebastian Seung, the EyeWirers P164 Analysis and modelling of transient firing rate changes in area MT in response to rapid stimulus feature changes Detlef Wegener, Lisa Bohnenkamp, Udo A. ...Pragathi Priyadharsini, Hima Mehta, V …
Kim, Shang Mu, Kevin L. Briggman, H. Sebastian Seung, the EyeWirers P164 Analysis and modelling of transient firing rate changes in a …
Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals.
Winkler TW, Rasheed H, Teumer A, Gorski M, Rowan BX, Stanzick KJ, Thomas LF, Tin A, Hoppmann A, Chu AY, Tayo B, Thio CHL, Cusi D, Chai JF, Sieber KB, Horn K, Li M, Scholz M, Cocca M, Wuttke M, van der Most PJ, Yang Q, Ghasemi S, Nutile T, Li Y, Pontali G, Günther F, Dehghan A, Correa A, Parsa A, Feresin A, de Vries APJ, Zonderman AB, Smith AV, Oldehinkel AJ, De Grandi A, Rosenkranz AR, Franke A, Teren A, Metspalu A, Hicks AA, Morris AP, Tönjes A, Morgan A, Podgornaia AI, Peters A, Körner A, Mahajan A, Campbell A, Freedman BI, Spedicati B, Ponte B, Schöttker B, Brumpton B, Banas B, Krämer BK, Jung B, Åsvold BO, Smith BH, Ning B, Penninx BWJH, Vanderwerff BR, Psaty BM, Kammerer CM, Langefeld CD, Hayward C, Spracklen CN, Robinson-Cohen C, Hartman CA, Lindgren CM, Wang C, Sabanayagam C, Heng CK, Lanzani C, Khor CC, Cheng CY, Fuchsberger C, Gieger C, Shaffer CM, Schulz CA, Willer CJ, Chasman DI, Gudbjartsson DF, Ruggiero D, Toniolo D, Czamara D, Porteous DJ, Waterworth DM, Mascalzoni D, Mook-Kanamori DO, Reilly DF, Daw EW, Hofer E, Boerwinkle E, Salvi E, Bottinger EP, Tai ES, Catamo E, Rizzi F, Guo F, Rivadeneira F, Guilianini F, Sveinbjornsson G, Ehret G, Waeber G, Biino G, Girotto G,… See abstract for full author list ➔ Winkler TW, et al. Commun Biol. 2022 Jun 13;5(1):580. doi: 10.1038/s42003-022-03448-z. Commun Biol. 2022. PMID: 35697829 Free PMC article.
Erratum: In vivo Mouse Model of Spinal Implant Infection.
[No authors listed] [No authors listed] J Vis Exp. 2023 May 5;(195). doi: 10.3791/6557. J Vis Exp. 2023. PMID: 37145962
The Authors section was updated from: Benjamin V. Kelley(1) Stephen D. Zoller(1) Danielle Greig(1) Kellyn Hori(1) Nicolas Cevallos(1) Chad Ishmael(1) Peter Hsiue(1) Rishi Trikha(1) Troy Sekimura(2) Thomas Olson(2) Ameen Chaudry(2) Michael M. Le(2) Anthony A. Scaduto …
The Authors section was updated from: Benjamin V. Kelley(1) Stephen D. Zoller(1) Danielle Greig(1) Kellyn Hori(1) Nicolas Cevallos(1) …
Four-dimensional flow cardiovascular magnetic resonance aortic cross-sectional pressure changes and their associations with flow patterns in health and ascending thoracic aortic aneurysm.
Bouaou K, Dietenbeck T, Soulat G, Bargiotas I, Houriez-Gombaud-Saintonge S, De Cesare A, Gencer U, Giron A, Jiménez E, Messas E, Lucor D, Bollache E, Mousseaux E, Kachenoura N. Bouaou K, et al. J Cardiovasc Magn Reson. 2024 Summer;26(1):101030. doi: 10.1016/j.jocmr.2024.101030. Epub 2024 Feb 24. J Cardiovasc Magn Reson. 2024. PMID: 38403074 Free PMC article.
This latter dataset was used for aortic morphology measurements, including AscAo maximal diameter (iD(MAX)) and volume, indexed to body surface area. 4D flow MRI data were used to estimate 1) cross-sectional local AscAo spatial ( P(S)) and temporal ( P(T)) pressure changes as wel …
This latter dataset was used for aortic morphology measurements, including AscAo maximal diameter (iD(MAX)) and volume, indexed to body surf …
Proceedings of the 3rd Biennial Conference of the Society for Implementation Research Collaboration (SIRC) 2015: advancing efficient methodologies through community partnerships and team science : Seattle, WA, USA. 24-26 September 2015.
Lewis C, Darnell D, Kerns S, Monroe-DeVita M, Landes SJ, Lyon AR, Stanick C, Dorsey S, Locke J, Marriott B, Puspitasari A, Dorsey C, Hendricks K, Pierson A, Fizur P, Comtois KA, Palinkas LA, Chamberlain P, Aarons GA, Green AE, Ehrhart MG, Trott EM, Willging CE, Fernandez ME, Woolf NH, Liang SL, Heredia NI, Kegler M, Risendal B, Dwyer A, Young V, Campbell D, Carvalho M, Kellar-Guenther Y, Damschroder LJ, Lowery JC, Ono SS, Carlson KF, Cottrell EK, O’Neil ME, Lovejoy TL, Arch JJ, Mitchell JL, Lewis CC, Marriott BR, Scott K, Coldiron JS, Bruns EJ, Hook AN, Graham BC, Jordan K, Hanson RF, Moreland A, Saunders BE, Resnick HS, Stirman SW, Gutner CA, Gamarra J, Vogt D, Suvak M, Wachen JS, Dondanville K, Yarvis JS, Mintz J, Peterson AL, Borah EV, Litz BT, Molino A, McCaughan SY, Resick PA, Pandhi N, Jacobson N, Serrano N, Hernandez A, Schreiter EZ, Wietfeldt N, Karp Z, Pullmann MD, Lucenko B, Pavelle B, Uomoto JA, Negrete A, Cevasco M, Kerns SEU, Franks RP, Bory C, Miech EJ, Damush TM, Satterfield J, Satre D, Wamsley M, Yuan P, O’Sullivan P, Best H, Velasquez S, Barnett M, Brookman-Frazee L, Regan J, Stadnick N, Hamilton A, Lau A, Regan J, Hamilton A, Stadnick N, Barnett M, Lau A, Brookma… See abstract for full author list ➔ Lewis C, et al. Implement Sci. 2016 Jun 23;11 Suppl 1(Suppl 1):85. doi: 10.1186/s13012-016-0428-0. Implement Sci. 2016. PMID: 27357964 Free PMC article.
Kirchner A23: Structuring complex recommendations: Methods and general findings Thomas J. Waltz, Byron J. Powell, Matthew J. Chinman, Laura J. Damschroder, Jeffrey L. ...Smith, Kimbree Brown, Karina Ramos, Nicole Thornton, Thomas J. Dishion, Elizabeth A. Stormshak, …
Kirchner A23: Structuring complex recommendations: Methods and general findings Thomas J. Waltz, Byron J. Powell, Matthew J. Chinman, …
Clinical sites of the Undiagnosed Diseases Network: unique contributions to genomic medicine and science.
Schoch K, Esteves C, Bican A, Spillmann R, Cope H, McConkie-Rosell A, Walley N, Fernandez L, Kohler JN, Bonner D, Reuter C, Stong N, Mulvihill JJ, Novacic D, Wolfe L, Abdelbaki A, Toro C, Tifft C, Malicdan M, Gahl W, Liu P, Newman J, Goldstein DB, Hom J, Sampson J, Wheeler MT; Undiagnosed Diseases Network; Cogan J, Bernstein JA, Adams DR, McCray AT, Shashi V. Schoch K, et al. Genet Med. 2021 Feb;23(2):259-271. doi: 10.1038/s41436-020-00984-z. Epub 2020 Oct 23. Genet Med. 2021. PMID: 33093671 Free PMC article.
Cross-sectional clinical cancer genomics community of practice survey analysis of provider attitudes and beliefs regarding the use of deceased family member tissue to guide living family member genetic cancer risk assessment.
Nehoray B, Slavin TP, Sun CL, Hurley K, King E, Tsang KK, Cervantes A, Mokhnatkin JV, Sand S, Mejia R, Reb A, Samimi G, Gray S, Blazer KR, Weitzel JN. Nehoray B, et al. J Genet Couns. 2022 Oct;31(5):1164-1172. doi: 10.1002/jgc4.1587. Epub 2022 May 26. J Genet Couns. 2022. PMID: 35617031 Free PMC article.
In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
Gamage TF, Barrus DG, Kevin RC, Finlay DB, Lefever TW, Patel PR, Grabenauer MA, Glass M, McGregor IS, Wiley JL, Thomas BF. Gamage TF, et al. Pharmacol Biochem Behav. 2020 Jun;193:172918. doi: 10.1016/j.pbb.2020.172918. Epub 2020 Apr 2. Pharmacol Biochem Behav. 2020. PMID: 32247816 Free PMC article.
In mice, EG-018 (100 mg/kg, 30 min) administered intraperitoneally (i.p.) did not produce effects in the tetrad or drug discrimination nor did it shift THC's ED(50) value in drug discrimination when administered before THC, suggesting EG-018 has negligible occupancy of brain CB(1 …
In mice, EG-018 (100 mg/kg, 30 min) administered intraperitoneally (i.p.) did not produce effects in the tetrad or drug discrimination nor d …
18 results